Bruker at HUPO 2026 - Functional Proteomics 2.0: From Biosamples to Bioinsights
Functional Proteomics 2.0: From Biosamples to Bioinsights
Meet Bruker at HUPO, Suntec Singapore Convention & Exhibition Centre, September 27 - October 1, and see how next-generation mass spectrometry is transforming 4D Multiomics and Functional Proteomics 2.0. Explore the latest innovations across our portfolio, including timsUltra AIP, timsOmni™, timsMetabo™, and more.
Join us throughout the week:
- Monday Lunch Seminar
“Functional Proteomics 2.0: Molecular Pathology, Spatial Context, and Functional Proteoforms”
Join us on Monday, September 28 at 12:15 for an engaging lunch seminar where you can enjoy a meal while exploring the latest advances in functional proteomics. Discover how advances in proteoform characterization, molecular pathology, and spatial proteomics are revealing a more complete and functional view of disease biology. - Tuesday Lunch Seminar
“Functional Proteomics 2.0: Reading Disease Signals Across the Immune and Circulating Proteome”
Join us on Tuesday, September 29 at 12:15 for our Lunch Seminar and learn how cutting-edge immunopeptidomics and biofluid proteomics workflows are uncovering disease mechanisms, actionable biomarkers, and new opportunities for precision medicine. - Visit our team at booth 120 to connect with our experts, learn more about our latest technologies, and see how Bruker solutions are enabling new levels of insight across a wide range of research applications.
Functional Proteomics 2.0: Molecular Pathology, Spatial Context, and Functional Proteoforms
Genomics tells us what could happen. Proteomics shows what is happening.
This session brings together cutting-edge advances in deep proteoform characterization, clinical proteomics implementation, and spatial tissue proteomics to address a core challenge: translating molecular measurements into biological and clinical insight. Our speakers will demonstrate how ion mobility-enabled workflows and multi-modal fragmentation strategies resolve proteoforms with unprecedented depth, exposing functional diversity hidden in traditional workflows. At the same time, real-world integration of proteomics into molecular pathology pipelines highlights what it takes to move from promise to routine application, particularly in complex tissue and disease types. Complementing this, emerging high-throughput spatial proteomics approaches are scaling tissue analysis while preserving biological context.
Together, these advances redefine what “functional proteomics” means: not just measuring proteins, but linking molecular form, spatial organization, and disease biology. The outcome is a more complete, mechanistic view of biology.
Featured presentations:
- Deep proteoform analysis by ion mobility spectrometry and multi-modal tandem mass spectrometry
Ole Nørregaard Jensen, Ph.D., Professor, Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark - From potential to practice – implementing proteomics in molecular pathology
Prof. Dr. med. Stephan Singer, Deputy Medical Director at the Institute of Pathology and Neuropathology, University of Tübingen, Germany - Scaling up and democratizing spatial tissue proteomics
Fabian Coscia, Ph.D., Group Leader, Spatial Proteomics Group, Max Delbrück Center, Berlin, Germany
Event details:
- Date: Monday, September 28, 2026
- Time: 12:15 - 13:15
- Location: Suntec Singapore Convention & Exhibition Centre
Ole Nørregaard Jensen, Ph.D.
Professor, University of Southern Denmark, Odense, Denmark
Prof. Dr. med. Stephan Singer
Deputy Medical Director at the Institute of Pathology and Neuropathology, University of Tübingen, Germany
Fabian Coscia, Ph.D.
Group Leader, Spatial Proteomics Group, Max Delbrück Center, Berlin, Germany
Functional Proteomics 2.0: Reading Disease Signals Across the Immune and Circulating Proteome
Disease biology ultimately plays out at the protein level, across immune interfaces and circulating systems.
This session focuses on how proteomics is decoding functional disease signals in immunopeptidomes and biofluids, bridging the gap between molecular detection and clinical relevance. From ultra-deep immunopeptidomics, enabling sensitive discovery of antigen repertoires directly presented by cells, to high-precision biofluid proteomics, revealing early risk signatures and systemic disease states, our speakers will showcase how 4D-Proteomics™ workflows capture biology that remains invisible to genomics and transcriptomics alone.
Applications span autoimmunity, oncology, and neonatal disease, highlighting how protein-level measurements can stratify risk, uncover mechanisms, and define actionable biomarkers. By interrogating both immune presentation and circulating proteomes, this session demonstrates how proteins provide a direct, functional readout of disease processes, and why they are essential for the next generation of biomarkers and precision medicine.
Featured presentations:
- Ultra-Deep Antigen Discovery: Immunopeptidomics on the timsUltra AIP
Anthony Purcell, Ph.D., Professor, Biochemistry & Molecular Biology, Monash University, Melbourne, Australia - What the Proteome Knows: Islet Autoimmunity Risk Revealed by diaPASEF Biofluid Proteomics
Laura Dagley, Ph.D., Head, Proteomics Laboratory, Walter and Eliza Hall Institute of Medical Research (WEHI), Parkville, Australia - Serum Proteomics Profiling in Newborns: Differences Compared to Adults serum and new molecular panel for neonatal Sepsis
Chiara Guerrera, Ph.D., IRHC, HDR, Head of Necker Proteomics, Faculty of Medicine, University Paris Cité, France
Event details:
- Date: Tuesday, September 29, 2026
- Time: 12:15 - 13:15
- Location: Suntec Singapore Convention & Exhibition Centre
Anthony Purcell, Ph.D.
Professor, Biochemistry & Molecular Biology, Monash University, Melbourne, Australia
Chiara Guerrera, Ph.D.
IRHC, HDR, Head of Necker Proteomics, Faculty of Medicine, University Paris Cité, France
Laura Dagley, Ph.D.
Head, Proteomics Laboratory, Walter and Eliza Hall Institute of Medical Research (WEHI), Parkville, Australia
Register Now and Secure Your Seat at the Lunch Seminars at HUPO 2026
See how next-generation mass spectrometry is transforming 4D Multiomics and Functional Proteomics 2.0.
Disclaimer
As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regard to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.
* Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a nongovernmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.
** A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.
Nur für die Forschung. Nicht für den Einsatz in klinischen diagnostischen Verfahren.